Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Legal Officer

SVP, Finance & Accounting

Chief Operating Officer

President and CEO

Chief Commercial Officer

CCO & Chief Strategy Officer

CFO, CBO

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-30	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-29	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-29	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-01-29	Premium	sold	Premium	Premium	Premium	SVP, Finance & Accounting
2024-01-29	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-01-24	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-24	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-02	Premium	acquired	Premium	Premium	Premium	SVP, Finance & Accounting
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2023-12-07	Premium	gifted	Premium	Premium	Premium	President and CEO
2023-12-07	Premium	gifted	Premium	Premium	Premium	President and CEO
2023-06-16	Premium	bought	Premium	Premium	Premium	-
2023-06-02	Premium	sold	Premium	Premium	Premium	President and CEO
2023-06-02	Premium	sold	Premium	Premium	Premium	President and CEO
2023-06-02	Premium	sold	Premium	Premium	Premium	President and CEO
2023-06-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-06-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-02-16	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2023-02-16	Premium	acquired	Premium	Premium	Premium	SVP, Finance & Accounting
2023-02-16	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-01-27	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-01-27	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-01-27	Premium	sold	Premium	Premium	Premium	SVP, Finance & Accounting
2023-01-27	Premium	sold	Premium	Premium	Premium	CCO & Chief Strategy Officer

KURA - Kura Oncology Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for KURA